The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.
 
Omid Yazdanpanah
No Relationships to Disclose
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Johann De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Acai Therapeutics; Amgen; Amunix (Inst); Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); MorphoSys (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Sheila Deymann
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Ghassan El-Haddad
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Bayer; Canon Medical System; Northstar Medical radioisotopes; TERUMO
Research Funding - Cellectar
Patents, Royalties, Other Intellectual Property - Patent Title: Locking Brakes For Enteral Feeding Tube Retention Member Inventor: Ghassan Elias El-Haddad Patent number: 10,492,999 Issue Date: December 3, 2019 Assignee: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
 
Ken Herrmann
Leadership - Aktis Oncology; Pharma15
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; SOFIE
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Orion; Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Pfizer
 
Diego Ospina Gonzalez
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Consulting or Advisory Role - FirstThought
Travel, Accommodations, Expenses - Novartis
 
Ayse Kendi
Consulting or Advisory Role - Novartis
Research Funding - Novartis; Novartis (Inst)
 
Bernd Krause
Honoraria - ITM Solucin; Janssen; Novartis
Consulting or Advisory Role - Bayer Health; ITM Solucin; Janssen; Novartis; PSI CRO Deutschland; TERUMO
Speakers' Bureau - Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Michael Morris
Employment - Memorial Sloan-Kettering Cancer Center
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Ambrx; Amgen; Arvinas; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clarity Pharmaceuticals; Convergent Therapeutics; Core Medica; Curium Pharma; Daiichi; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; ITM Isotope Technologies Munich; Lantheus Medical Imaging; Mashup Media; Pfizer; POINT Biopharma; Progenics; Telix Pharmaceuticals; Transtherabio; Z-Alpha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; APCCC; AstraZeneca; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Amgen; Bayer; Halda Therapeutics; Janssen Oncology; Novartis; Wren Laboraties
 
James Nagarajah
Honoraria - Bayer; ITM Isotope Technologies Munich; Novartis; POINT Biopharma
Consulting or Advisory Role - ITM Isotope Technologies Munich; Novartis
Speakers' Bureau - Bayer; Novartis
Research Funding - Advanced Biochemical Compounds (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Luke Nordquist
Stock and Other Ownership Interests - Clarity Pharmaceuticals
Travel, Accommodations, Expenses - Fusion Pharmaceuticals
 
Alton Sartor
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Lilly; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Intellisphere; Lantheus Medical Imaging; Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bayer; Clarity Pharmaceuticals; EMD Serono; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; MacroGenics; Merck; Novartis; Pfizer; Point Biopharma; Ratio; Sanofi; Telix Pharmaceuticals; TeneoBio
Research Funding - Advanced Accelerator Applications (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Novartis (Inst); POINT Biopharma (Inst); Sanofi (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - Bayer; Lantheus Medical Imaging; Sanofi
 
Kambiz Rahbar
Consulting or Advisory Role - Advanced Biochemical Compounds; Bayer; Novartis; Pharmtrace; Urotrial
Speakers' Bureau - Advanced Biochemical Compounds; Bayer; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Advanced Biochemical Compounds; Bayer
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Nitin Vaishampayan
Consulting or Advisory Role - Alkermes (I); Bayer (I); Bristol-Myers Squibb/Pfizer (I); Exelixis (I); Gilead Sciences (I); Merck (I); Novartis; Novartis (I); Pfizer (I)
Speakers' Bureau - Bayer (I); Exelixis (I)
Research Funding - Merck (I)
 
Ye Yue
Employment - Novartis
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AimedBio; AstraZeneca; aveo; Bayer; Bicycle Therapeutics; Eisai; Exelixis; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Amgen; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Myovant Sciences; Pfizer; Sanofi
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eikon Therapeutics; Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); navir (Inst); Novartis (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Janssen